CME/CE

Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders

5:15

Faculty: Komal Jhaveri, MD, FACP

Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for…